Alacrita is life science consulting for a networked age. You can expect the caliber and capabilities of a top-ranked consulting firm, but you'll find a difference in our expertise. We've built our team carefully, hand-picking only those consultants with deep domain knowledge and senior business experience. With more than 200 successful client assignments each year, we're proving what's possible for commercial life sciences in a new era of opportunity.
Athena Market Access Solutions
Founded in 2016 Athena Market Access Solutions specialises in providing pricing and reimbursement related solutions to organisations in the life sciences industry.
The company is run by Maximilian Lebmeier who has over a decade experience in Global, European and UK/Irish market access roles in the pharmaceutical industry. He has worked on over 130 health technology assessments (HTAs) in a wide range of disease areas including rheumatology, dermatology, cardiology, hepatology, transplantation, infectious diseases, and oncology. Besides of his company duties he has worked intensively with industry associations on market access and HTA related activities.
Athena’s services stretch throughout the lifecycle of a product from payer and reimbursement input into clinical development, early health economics and outcomes research and pricing activities alongside clinical trials and regulatory processes, the preparation of reimbursement submissions, the navigation of pricing and reimbursement procedures, input into clinical guidelines, market access and competitive pipeline and portfolio reviews, training and strategic consultancy.
Athena Market Access Solutions Ltd. is co‐organiser of the ‘Kendal Collaboration’, a group of small businesses and independent professionals with expertise in all aspects of health economics and outcomes research.
Athena’s customers include biotechnology companies, pharmaceutical companies, as well as a consultancies.
Established in 2005, Boyd provides a range of expertise and skills central to the development of pharmaceutical and biotechnology medicinal products. Boyds' consultancy services offer a cost-effective solution for those requiring expert assistance in order to expediate development, add value to products and reach key milestones.
Whether it relates to a single issue or a long-term commitment to a development team, Boyds can chart the innovative course that great science demands.
Strategic pharmaceutical and pre-clinical consulting services. Critical due diligence, rationalisation and evaluation of IP portfolios, academic research and early-stage/preclinical projects - ultimately looking to de-risk and increase commercial attractiveness and licensing potential.
Advising and supporting academic institutions and start-up companies on out-sourcing strategies - looking for cost-effective solutions and accelerating the speed of progression and completion of projects.
Oversight and management of outsourced CMC and preclinical projects.
Undertaking due diligences on behalf of organisations in- and out-licencing development drug candidates.
Exploring innovative business models and opportunities for funding between academia and the out-sourcing network, looking to create collaborative win-win partnerships to progress projects.
Attending conferences and exhibitions on behalf of clients, evaluating new product opportunities and service providers.
From drug discovery to commercialisation - we support the full spectrum.
Business Development and Licensing - Need support to acquire, divest or license a product or project? That's what we do. Regulatory Affairs, Pharmacovigilance - If you need support with your regulatory affairs, regulatory strategy or pharmacovigilance needs, we can arrange this through our trusted partner organisation. Wide Network - Projects at initial scientific concepts? Products at commercialisation and reimbursement stage? Our partners will help. Due Diligence and Auditing - Looking for support for due diligence, or auditing of partners? We can arrange all this.
Pneumagen is using its platform technology, GlycoTarge™, to develop glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer.
Pneumagen’s lead product, Neumifil™, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV) and Respiratory Synctial Virus (RSV) infections. When administered intranasally in preclinical models, Neumifil™ has demonstrated prevention, treatment and post-exposure prophylaxis of IFV infection with no observed toxicity. Pneumagen’s mCBM, in development for cancer, isknown as Neumonco™. In vitro data have demonstrated that mCBMs target and enter cancer cells, reducing cell proliferation, migration, metabolism and differentiation.
Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Please visit www.pneumagen.com for more information.